DMAPT
* Please be kindly noted products are not for therapeutic use. We do not sell to patients.
| Category | Bioactive by-products |
| Catalog number | BBF-04346 |
| CAS | 870677-05-7 |
| Molecular Weight | 293.40 |
| Molecular Formula | C17H27NO3 |
| Purity | ≥99% |
Online Inquiry
Description
DMAPT, an analogue of parthenolide, has been found to be effective in restraining the proliferation and metastasis of sorts of tumor cells through targeting NF-κB. DMAPT has been reported as an antiviral, anti-HIV and anti-Hepatitis C virus agent.
Specification
| Synonyms | Dimethylamino Parthenolide; NSC-734325; Oxireno(9,10)cyclodeca(1,2-b)furan-9(1ah)-one, 8-((dimethylamino)methyl)-2,3,6,7,7a,8,10a,10b-octahydro-1a,5-dimethyl-, (1aR,4E,7aS,8S,10aS,10bR)- |
| Storage | Store at -20°C |
| IUPAC Name | (1S,2R,4R,7E,11S,12S)-12-[(dimethylamino)methyl]-4,8-dimethyl-3,14-dioxatricyclo[9.3.0.02,4]tetradec-7-en-13-one |
| Canonical SMILES | CC1=CCCC2(C(O2)C3C(CC1)C(C(=O)O3)CN(C)C)C |
| InChI | InChI=1S/C17H27NO3/c1-11-6-5-9-17(2)15(21-17)14-12(8-7-11)13(10-18(3)4)16(19)20-14/h6,12-15H,5,7-10H2,1-4H3/b11-6+/t12-,13+,14-,15+,17+/m0/s1 |
| InChI Key | UJNSFDHVIBGEJZ-SQJADDCJSA-N |
| Source | Synthetic |
Properties
| Appearance | White Crystalline Solid |
| Antibiotic Activity Spectrum | Neoplastics (Tumor); Viruses |
| Boiling Point | 419.7±45.0°C at 760 mmHg |
| Melting Point | 149-143°C |
| Density | 1.1±0.1 g/cm3 |
| Solubility | Soluble in Ethanol, DMF, DMSO |
Reference Reading
1. DMAPT‑D6 induces death‑receptor‑mediated apoptosis to inhibit glioblastoma cell oncogenesis via induction of DNA damage through accumulation of intracellular ROS
Jiu-Hong Huang, Ya-Jun Zhang, Zhi-Gang Xu, Liu-Jun He, Zhong-Zhu Chen, Dian-Yong Tang, Yong Li, Dong-Lin Yang, Hong-Xia Qin Oncol Rep . 2021 Mar;45(3):1261-1272. doi: 10.3892/or.2021.7932.
Glioblastoma (GBM) is an aggressive malignancy with a high rate of tumor recurrence after treatment with conventional therapies. Parthenolide (PTL), a sesquiterpene lactone extracted from the herb Tanacetum parthenium or feverfew, possesses anticancer properties against a wide variety of solid tumors. In the present study, a series of PTL derivatives were synthesized and screened. An inhibitor, dimethylaminoparthenolide (DMAPT)‑D6, a derivative of the PTL prodrug DMAPT in which the hydrogen of the dimethylamino group is substituted for the isotope deuterium, induced significant cytotoxicity in GBM cells in vitro and induced cell cycle arrest at the S‑phase in a dose‑dependent manner. Furthermore, mechanistic investigation indicated that through increasing the levels of intracellular accumulation of reactive oxygen species (ROS), DMAPT‑D6 triggered DNA damage and finally death receptor‑mediated extrinsic apoptosis in GBM cells, suggesting that DNA damage induced by DMAPT‑D6 initiated caspase‑dependent apoptosis to remove damaged GBM cells. Taken together, these data suggested that ROS accumulation following treatment with DMAPT‑D6 results in DNA damage, and thus, death‑receptor‑mediated apoptosis, highlighting the potential of DMAPT‑D6 as a novel therapeutic agent for the treatment of GBM.
2. DMAPT is an Effective Radioprotector from Long-Term Radiation-Induced Damage to Normal Mouse Tissues In Vivo
Katherine L Morel, Rebecca J Ormsby, Christopher J Sweeney, Pamela J Sykes, Sonja Klebe Radiat Res . 2019 Aug;192(2):231-239. doi: 10.1667/RR15404.1.
While radiotherapy is widely used in cancer treatment, the benefits can be limited by radiation-induced damage to neighboring healthy tissues. We previously demonstrated in mice that the anti-inflammatory compound dimethylaminoparthenolide (DMAPT) selectively induces radiosensitivity in prostate tumor tissue from transgenic adenocarcinoma of mouse prostate (TRAMP) mice, while simultaneously protecting healthy tissues from 6 Gy whole-body radiation-induced apoptosis. Here, we examined the radioprotective effect of DMAPT on fibrosis in normal tissues after a partial-body fractionated radiation protocol that more closely mimics the image-guided fractionated radiotherapy protocols used clinically. Male C57BL/6J mice, 16 weeks old, received 20 Gy fractionated doses of X rays (2 Gy daily fractions, five days/week for two weeks) or sham irradiation to the lower abdomen, with or without a prior 20 mGy dose to mimic an image dose. In addition, mice received thrice weekly DMAPT (100 mg/kg by oral gavage) or vehicle control from 15 weeks of age until time of analysis at 6 weeks postirradiation. In the absence of exposure to radiation, there were no significant differences observed in the tissues of DMAPT and vehicle-treated mice (P> 0.05). DMAPT treatment significantly reduced radiation-induced testis weight loss by 60.9% (P< 0.0001), protected against a decrease in the seminiferous tubule diameter by 42.1% (P< 0.0001) and largely preserved testis morphology. Inclusion of the image dose had no significant effect on testis mass, seminiferous tubule diameter or testis morphology. DMAPT reduced radiation-induced fibrosis in the corpus cavernous region of the penis (98.1% reduction,P= 0.009) and in the muscle layer around the bladder (80.1% reduction,P= 0.0001). There was also a trend towards reduced collagen infiltration into the submucosal and muscle layers in the rectum. These results suggest that DMAPT could be useful in providing protection from the radiation-induced side effects of impotence and infertility, urinary incontinence and fecal urgency resulting from prostate cancer radiotherapy. DMAPT is a very well-tolerated drug and can conveniently be delivered orally without strict time windows relative to radiation exposure. Protection of normal tissues by DMAPT could potentially be useful in radiotherapy of other cancer types as well.
3. Actinomycin-D and dimethylamino-parthenolide synergism in treating human pancreatic cancer cells
Gauri Lamture, Peter A Crooks, Michael J Borrelli Drug Dev Res . 2018 Sep;79(6):287-294. doi: 10.1002/ddr.21441.
Preclinical Research & Development Pancreatic cancer is the third leading cause of death in the US with a poor 5-year survival rate of 8.5%. A novel anti-cancer drug, dimethylamino parthenolide (DMAPT), is the water-soluble analog of the natural sesquiterpene lactone, parthenolide. The putative modes of action of DMAPT are inhibition of the Nuclear chain factor kappa-light-chain enhancer of activated B cells (NFκB) pathway and depletion of glutathione levels; the latter causing cancer cells to be more susceptible to oxidative stress-induced cell death. Actinomycin-D (ActD) is a polypeptide antibiotic that binds to DNA, and inhibits RNA and protein synthesis by inhibiting RNA polymerase II. A phase 2 clinical trial indicated that ActD could be a potent drug against pancreatic cancer; however, it was not a favored drug due to toxicity issues. New drug entities and methods of drug delivery, used alone or in combination, are needed to treat pancreatic cancer more effectively. Thus, it was postulated that combining DMAPT and ActD would result in synergistic inhibition of Panc-1 pancreatic cancer cell growth because DMAPT's inhibition of NFκB would enhance induction of apoptosis by ActD, via phosphorylation of c-Jun, by minimizing NFκB inhibition of c-Jun phosphorylation. Combining these two drugs induced a higher level of cell death than each drug alone. A fixed drug ratio of DMAPT: ActD (1,200:1) was used. Data from metabolic (MTT) and colony formation assays were analyzed for synergism with CompuSyn software, which utilizes the Chou-Talalay equation. The analyses indicated synergism and moderate synergism at combination concentrations of DMAPT/ActD of 12/0.01 and 18/0.015 μM, respectively.
Recommended Products
| BBF-05862 | Epirubicin | Inquiry |
| BBF-00677 | 3-Amino-3-deoxy-D-glucose | Inquiry |
| BBF-03754 | CASTANOSPERMINE | Inquiry |
| BBF-01693 | Doxorubicin EP Impurity A (Daunorubicin) | Inquiry |
| BBF-02642 | Lactonamycin | Inquiry |
| BBF-03755 | Actinomycin D | Inquiry |
Bio Calculators
* Our calculator is based on the following equation:
Concentration (start) x Volume (start) = Concentration (final) x Volume (final)
It is commonly abbreviated as: C1V1 = C2V2
* Total Molecular Weight:
g/mol
Tip: Chemical formula is case sensitive. C22H30N4O √ c22h30n40 ╳
